脊髓造影实践的关键评估:呼吁合理修订指南
该研究通过电子邮件调查美国神经放射学会会员,了解脊髓造影前停用降低癫痫阈值药物的情况及造影后癫痫发生率。结果显示57%的受访者不停药,97%从未遇到癫痫发作,停药与不停药组间癫痫发生率无统计学显著差异(OR=2.13;95%CI,0.91-4.98;P=.08),多数使用非离子低渗对比剂。作者据此提出,在当前非离子水溶性对比剂下,停药可能不必要且可能有害,支持修订现有建议。
要点
- 57%的受访者脊髓造影前不停用降低癫痫阈值药物,97%从未遇到造影后癫痫发作。
- 停药与不停药组间造影后癫痫发生率无统计学显著差异(OR=2.13;95%CI,0.91-4.98;P=.08)。
- 95%的受访者使用非离子低渗对比剂,作者认为当前对比剂下停药可能不必要且可能有害。
核心结论
- 调查显示脊髓造影准备和术后监测实践差异很大;停药与不停药组间癫痫发生率无显著差异;作者提出在当前非离子水溶性对比剂下停药不必要且可能有害,支持修订现有建议。
研究设计与样本
- 电子邮件调查美国神经放射学会会员,共700份回复,询问过去5年造影后癫痫例数、是否有停用降低癫痫阈值药物的机构政策及所用对比剂类型,并比较停药与不停药组的癫痫频率。
诊断标准与关键数值
- 停药组与不停药组造影后癫痫发生率比较:OR=2.13;95%CI,0.91-4.98;P=.08。
- 57%的受访者报告脊髓造影前不停用降低癫痫阈值药物。
- 97%的受访者报告从未有患者发生造影后癫痫。
- 95%的受访者报告使用非离子低渗对比剂。
临床应用与阅片要点
- 作者认为,在当前非离子水溶性对比剂下,停用降低癫痫阈值药物不必要,且在某些情况下可能有害。
- 作者提出该工作支持修订脊髓造影前停用此类药物的现有建议。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: Patient preparation for myelography and postprocedural monitoring varies widely between practices, despite published guidelines. Our aim was to examine the current practice variations in discontinuing reportedly seizure threshold-lowering medications before myelography and to assess the reported incidence of postmyelographic seizures.
MATERIALS AND METHODS: An e-mail survey was sent to American Society of Neuroradiology members concerning the number of postmyelographic seizures experienced in the past 5 years, the presence of an institutional policy for discontinuing seizure threshold-lowering medications, and the type of myelographic contrast used. We compared the postmyelographic seizure frequency in the responses.
RESULTS: Of 700 survey responses, 57% reported that they do not discontinue seizure threshold-lowering medications before myelography. Most (97%) indicated never having a patient experience a seizure following myelography. The number of postmyelographic seizures between those who discontinue seizure threshold-lowering medications and those who do not was not statistically significant (OR = 2.13; 95% CI, 0.91-4.98; P = .08). Most (95%) reported using nonionic hypo-osmolar agents.
CONCLUSIONS: Survey results revealed widely variable practices for patient myelography preparation and postprocedural monitoring. We found no difference in reported seizures between those who discontinued seizure threshold-lowering medications and those who did not. In light of our findings, we propose that discontinuing reportedly seizure threshold-lowering medications is not warranted with the current nonionic water-soluble contrast agents and may be potentially harmful in some instances. This work supports revision of existing recommendations to withhold such medications before myelography.
引用
- Shah LM, Kranz PG, Anzai Y, et al. Critical Assessment of Myelography Practices: A Call for Rational Guideline Revision. AJNR Am J Neuroradiol. 2018. PMID: 30385469. doi:10.3174/ajnr.A5867
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。